112 related articles for article (PubMed ID: 1612504)
1. Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma.
Tomás C; Kauppila A
Gynecol Oncol; 1992 Jun; 45(3):279-83. PubMed ID: 1612504
[TBL] [Abstract][Full Text] [Related]
2. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.
Kauppila A; Puistola U; Risteli J; Risteli L
Cancer Res; 1989 Apr; 49(7):1885-9. PubMed ID: 2924328
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Kauppila A
Ann Med; 1990 Apr; 22(2):115-21. PubMed ID: 2361007
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Vuori J; Kauppila A
Cancer; 1990 Dec; 66(11):2399-406. PubMed ID: 2245396
[TBL] [Abstract][Full Text] [Related]
5. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma.
Rose PG; Terrien JM; Baker S
J Surg Oncol; 1994 Jul; 56(3):168-71. PubMed ID: 8028348
[TBL] [Abstract][Full Text] [Related]
6. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
8. CA 125 surveillance and second-look laparotomy in ovarian carcinoma.
Atack DB; Nisker JA; Allen HH; Tustanoff ER; Levin L
Am J Obstet Gynecol; 1986 Feb; 154(2):287-9. PubMed ID: 3456202
[TBL] [Abstract][Full Text] [Related]
9. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.
Risteli L; Risteli J; Puistola U; Tomás C; Zhu GG; Kauppila A
Acta Obstet Gynecol Scand Suppl; 1992; 155():99-103. PubMed ID: 1502898
[TBL] [Abstract][Full Text] [Related]
10. Value of serum 125Ca levels: does the result preclude second look?
Potter ME; Moradi M; To AC; Hatch KD; Shingleton HM
Gynecol Oncol; 1989 May; 33(2):201-3. PubMed ID: 2703182
[TBL] [Abstract][Full Text] [Related]
11. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
12. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Lammi L; Kinnula V; Lähde S; Risteli J; Pääkkö P; Lakari E; Ryhänen L
Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651
[TBL] [Abstract][Full Text] [Related]
13. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
14. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.
Santala M; Risteli J; Risteli L; Puistola U; Kacinski BM; Stanley ER; Kauppila A
Br J Cancer; 1998 Jun; 77(11):1825-31. PubMed ID: 9667653
[TBL] [Abstract][Full Text] [Related]
16. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.
Mogensen O; Mogensen B; Jakobsen A; Sell A
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1835-7. PubMed ID: 3220081
[TBL] [Abstract][Full Text] [Related]
17. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of second-look laparotomy for patients with epithelial ovarian carcinoma.
Kamura T; Tsukamoto N; Saito T; Kaku T; Matsuyama T; Nakano H
Int J Gynaecol Obstet; 1990 Oct; 33(2):141-7. PubMed ID: 1976547
[TBL] [Abstract][Full Text] [Related]
20. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
